GIPR and triple-negative breast carcinoma: Interestingly, a recent study has reported that retatrutide, a triple agonist of glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and GLP-1R, alleviated tumor growth and chemotherapy resistance in obesity-associated triple-negative breast cancer (65).